Future clinical implications for farnesyltransferase inhibitors in hematologic malignancies.
Progress in molecular biology over the past several years has advanced our understanding of the pathology of leukemia. Researchers have identified a long list of the cytogenetic and molecular abnormalities associated with these diseases. However, a significant unmet need remains for medical therapies for leukemia, especially in older patients.